RecruitingPhase 3NCT04704947

Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis

Clinical Study Evaluating Selective or Nonselective Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis

Sponsor

Sherief Abd-Elsalam

Enrollment

50 participants

Start Date

Oct 1, 2017

Study Type

INTERVENTIONAL

Conditions

Beta Blocker Toxicity

Summary

Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis

Eligibility

Min Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called alendronate sodium, a drug called cardio-selective beta blocker group, and others for people with beta blocker toxicity. The study is currently recruiting participants at 1 location. People eligible for this study include aged 50 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGnonselective beta blocker

nonselective beta blocker

DRUGcardio-selective beta blocker group

cardio-selective beta blocker group

DRUGalendronate sodium

alendronate sodium

Locations(1)

Sherief Abd-Elsalam

Tanta, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04704947